For the Inventor, By the Inventor

Enter assignee name

Leuven, Belgium

Thrombogenics Nv

USPTO Granted Patents = 21

% Expired Patents = 85.7

CIPO Patents = 2

EPO Patents = 10

Trademarks = 1

Forward Citations = 82

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Marc De Smet (10 out of 10 patents)

Steve Pakola (10 out of 10 patents)

Jean-Marie Stassen (4 out of 6 patents)

4. Peter Carmeliet (3 out of 21 patents)

5. Richard Reinier Zwaal (3 out of 4 patents)

6. Désiré Collen (3 out of 10 patents)

7. Ingeborg Stalmans (2 out of 2 patents)

8. Luc Schoonjans (2 out of 3 patents)

9. Claudia Fromond (1 out of 6 patents)

10. Hoa Thu Ngo (1 out of 1 patent)

11. Sofie Notebaert (1 out of 1 patent)

12. Emmanuel Sneyders (1 out of 1 patent)

13. Jean Marie Stassen (1 out of 1 patent)

14. Hans Nicasy (1 out of 1 patent)

15. Bart Jonckx (1 out of 1 patent)

21 patents: Sort by Forward Citations

1. 9884910 - Anti-PDGF-C antibodies (2018-02-06),

2. 9770494 - Pharmacological vitreolysis (2017-09-26),

3. 9644196 - Plasminogen and plasmin variants (2017-05-09),

4. 9445078 - Stereo-vision system (2016-09-13),

5. 9226953 - Variants of plasminogen and plasmin (2016-01-05),

6. 9186394 - Pharmacological vitreolysis (2015-11-17),

7. 9089552 - Improving trabeculectomy outcome by administering an anti-placental growth factor antibody (2015-07-28),

8. 9085617 - Anti-angiogenic therapy (2015-07-21),

9. 8993323 - Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells (2015-03-31),

10. 8920794 - Method for treating filtration failure after trabeculectomy surgery (2014-12-30),

11. 8834869 - Pharmacological vitreolysis (2014-09-16),

12. 8758748 - Anti-angiogenic therapy (2014-06-24),

13. 8747842 - Pharmacological vitreolysis (2014-06-10),

14. 8697444 - Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells (2014-04-15),

15. 8460655 - Pharmacological vitreolysis (2013-06-11),

Thrombogenics NV is a biotechnology company based in Leuven, Belgium, specializing in the development of innovative therapies for eye diseases and other medical conditions. The company focuses on advancing treatments that target vascular health, particularly in the field of retinal diseases. Thrombogenics is committed to research and development, leveraging cutting-edge technology to create effective solutions that improve patient outcomes and address unmet medical needs in the healthcare sector.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

21 Patents

#9 in Leuven

#154 in Belgium

#29,928 in the World

Leuven, Belgium

Thrombogenics Nv

Forward Citations = 82

16 inventors:

Marc De Smet (10 out of 10 patents)

Steve Pakola (10 out of 10 patents)

Jean-Marie Stassen (4 out of 6 patents)

4. Peter Carmeliet (3 out of 21 patents)

5. Richard Reinier Zwaal (3 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…